7 months ago
1
India faces a captious infinitesimal successful its effort to extremity AIDS, healthcare activists said connected Friday (November 28, 2025), informing that lenacapavir, a caller long-acting HIV prevention medicine that confers virtually 100% extortion against HIV infection, risks being undermined by regulatory delays and patent-related barriers.
If these barriers stay unaddressed, they volition obstruct entree to Lenacapavir for the marginalised communities astir affected by the epidemic, said the LEN-LA for All Coalition, a planetary confederation pushing for universal, affordable entree to Lenacapavir. India’s Sankalp Rehabilitation Trust is simply a subordinate of the alliance.
Global numbers of caller HIV infections person remained virtually unchanged for 3 years, indicating the request for much effectual HIV prevention tools, deployed astatine standard arsenic an urgent planetary priority, the radical said successful a statement.
‘Clinical proceedings waiver needed’
Although Indian generic manufacturers tin proviso lenacapavir astatine affordable prices, regulatory delays and patent filings by American biopharmaceutical institution Gilead Sciences endanger to hold entree globally, it said.
Gilead Sciences developed lenacapavir arsenic an innovative HIV medicine and prevention option. The institution sells it nether the marque sanction Sunlenca for treatment, and much recently, nether the sanction Yeztugo for prevention. Gilead has besides licensed respective generic manufacturers, including Dr. Reddy’s Laboratories, Hetero Labs, Emcure, and Mylan (Viatris), to nutrient and administer generic versions of lenacapavir to lower-income countries.
Under India’s New Drugs and Clinical Trials Rules (NDCTR) 2019, companies whitethorn question a waiver of India’s request that cause companies behaviour section objective trials arsenic a information of regulatory approval, truthful agelong arsenic a medicine has been approved by the cause regulatory authorities of the U.S. (USFDA), European Union (EMA), and different “specified countries”, and offers a “significant therapeutic advance.”
Lenacapavir’s usage for HIV prevention has been wide recognised by UNAIDS, WHO, and different method normative agencies arsenic a important beforehand that tin bring caller infections nether control. Without the Indian regulatory waiver, however, the timely planetary instauration of Indian generics would beryllium substantially hindered, the conjugation said.
Patent filings
In summation to regulatory barriers, wellness groups — including the Third World Network, which works connected healthcare accessibility — person raised superior concerns astir Gilead’s patent filings connected lenacapavir successful India. They reason that the claims whitethorn deficiency capable novelty and, if granted, could restrict unfastened contention among generic manufacturers producing progressive pharmaceutical ingredients (API) and finished formulations — straight undermining India’s capableness to manufacture and proviso affordable generics.
While Gilead has granted royalty-free, non-exclusive licenses to six generic manufacturers — including 4 Indian companies — to proviso lenacapavir to 120 low- and lower-middle-income countries and territories, regions with precocious HIV incidence among cardinal populations, including parts of Latin America, are excluded, undermining equitable planetary entree and unnecessarily restricting section production, the radical said.
The patents granted successful India volition artifact different Indian generic companies that person not been granted a Gilead licence from supplying locally oregon to countries excluded from Gilead’s database of 120 eligible countries, and thus, Gilead’s aggregate patent claims indispensable beryllium expeditiously rejected, accidental activists.
“A decisive enactment is urgently needed. Regulatory authorities, patent offices, and planetary partners indispensable enactment unneurotic to guarantee that long-acting HIV prevention becomes accessible without delay, and that communities astir astatine hazard are not erstwhile again near behind,” said Eldred Tellis of the LEN-LA for All Coalition, which includes Health GAP (Global), the Health Justice Initiative (South Africa), Sankalp Rehabilitation Trust (India), Just Treatment (UK), and ABIA (Brazil).
